MEDIBANK PRIVATE LIMITED (MPL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MPL

MPL - MEDIBANK PRIVATE LIMITED

FNArena Sector : Insurance
Year End: June
GICS Industry Group : Insurance
Debt/EBITDA: N/A
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Medibank Private is the largest Australian private health insurance provider. Previously an Australian Government business enterprise, established by the Whitlam government in 1975, it was privatised in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.42

24 Mar
2025

0.050

OPEN

$4.37

1.14%

HIGH

$4.43

4,298,995

LOW

$4.37

TARGET
$4.637 4.9% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AUB . CVW . FCL . GDG . HLI . IAG . NHF . NOL . QBE . SDF . SUN . TWR .
FNARENA'S MARKET CONSENSUS FORECASTS
MPL: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 17.9 22.5 xxx
DPS (cps) xxx 16.6 17.5 xxx
EPS Growth xxx - 3.7% 26.0% xxx
DPS Growth xxx 13.7% 5.5% xxx
PE Ratio xxx N/A 19.6 xxx
Dividend Yield xxx N/A 4.0% xxx
Div Pay Ratio(%) xxx 92.8% 77.8% xxx

Dividend yield today if purchased 3 years ago: 5.42%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.80

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 9.4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx17.9
DPS All xxxxxxxxxxxxxxx16.6
Sales/Revenue xxxxxxxxxxxxxxx8,021.6 M
Book Value Per Share xxxxxxxxxxxxxxx83.7
Net Operating Cash Flow xxxxxxxxxxxxxxx988.4 M
Net Profit Margin xxxxxxxxxxxxxxx6.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx22.44 %
Return on Invested Capital xxxxxxxxxxxxxxx21.57 %
Return on Assets xxxxxxxxxxxxxxx10.85 %
Return on Equity xxxxxxxxxxxxxxx22.44 %
Return on Total Capital xxxxxxxxxxxxxxx31.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx554.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx67 M
Long Term Debt xxxxxxxxxxxxxxx152 M
Total Debt xxxxxxxxxxxxxxx218 M
Goodwill - Gross xxxxxxxxxxxxxxx402 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx691 M
Price To Book Value xxxxxxxxxxxxxxx4.46

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx57.6 M
Capex % of Sales xxxxxxxxxxxxxxx0.72 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx385 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx3,060 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

03/03/2025

3

Hold

$4.52

2.26%

First half net profit from Medibank Private beat estimates, largely on stronger health insurance. Morgans upgrades estimates for FY25 and FY26 by 3-4%.

While the performance appears "pretty solid" and guidance on claims is more favourable, the broker notes the stock is trading on around 19x FY25 earnings and is therefore considered as fair value at this point of the cycle.

Hold maintained. Target rises to $4.52 from $4.11.

FORECAST
Morgans forecasts a full year FY25 dividend of 17.20 cents and EPS of 21.40 cents.
Morgans forecasts a full year FY26 dividend of 18.20 cents and EPS of 22.70 cents.

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Goldman Sachs

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

06/03/2025

3

Neutral

$4.40

-0.45%

Medibank Private's 1H25 underlying net profit beat Jarden's forecast by 5% on strong results from health insurance. Net margin was 40bps higher at 8.5% vs the broker's forecast.

The broker sees headwinds from NSW bed levy and hospital indexation, but forecasts margin jaws to remain positive with the 2025 premium rate announcement of a 3.99% increase helping the FY26 outlook.

The broker estimates FY25 net margin of 8.9% vs 8.8% in FY24 FY25 EPS forecast cut by -0.4% but FY26 lifted by 5.2%. Target price is $4.40 and rating maintained at Neutral.

FORECAST
Jarden forecasts a full year FY25 dividend of 17.50 cents and EPS of 19.50 cents.
Jarden forecasts a full year FY26 dividend of 18.70 cents and EPS of 23.10 cents.
Access Extra Coverage Research History >

MPL STOCK CHART

FNArena News on MPL

1
In Brief: Is The Aussie Market Misunderstood?

Mar 21 2025 - Weekly Reports
2
Rudi’s View: Post February Conviction Calls

Mar 13 2025 - Rudi's View
3
Australian Broker Call *Extra* Edition – Mar 06, 2025

Mar 06 2025 - Daily Market Reports
4
FNArena Corporate Results Monitor – 28-02-2025

Feb 28 2025 - Australia
5
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View

Latest Insurance News

1
Insurers To Pamper Shareholders With Buybacks

Jan 24 2025 - Australia
2
IAG Shares Breaking Out

Jan 21 2025 - Technicals
3
ESG Focus: The Little Big Things – 21-11-2024

Nov 21 2024 - ESG Focus
4
New-Look Suncorp Ready To Rumble

Nov 14 2024 - Australia
5
Steadfast’s Long March

Jul 02 2024 - Australia
6
AUB Group Shares Poised For Break-Out

Jun 13 2024 - Technicals
7
SMSFundamentals: Older People Are Life Insurers’ Future Challenge

Oct 26 2023 - SMSFundamentals
8
Australian Insurers And The Weather

Oct 19 2023 - Feature Stories
9
Steadfast Group’s US Entry Full Of Promise

Oct 11 2023 - Australia
10
Pros And Cons Of Insurance Companies

Aug 02 2023 - Australia